Viewing nowCombinationCidiem Extended Release Tablets 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 202300598 · Approved 2023.02.17 · Insurance code 645907410
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling blood sugar levels when combined with diet and exercise. Sitagliptin and metformin work together to effectively lower blood sugar levels, thereby facilitating smoother blood sugar management. Therefore, this medication is used to improve blood sugar control in type 2 diabetes.
In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take one 100/1000 mg extended-release tablet once daily. Patients taking 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently being treated with metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Take This Drug). 2. Patients being treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because of its metformin component (see Precautions for Use, 2. Patients Who Must Not Take This Drug).
This medication contains both sitagliptin and metformin and is primarily used for the treatment of type 2 diabetes. First, there is a possibility of severe allergic reactions during the use of this medication; if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, you should stop taking it immediately and consult a doctor. Furthermore, there is a risk of pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, vomiting, or fever occur, you should visit a hospital immediately. The metformin component in this medication can cause lactic acidosis, a rare but potentially fatal metabolic disorder; therefore, if symptoms such as sudden difficulty breathing, muscle pain, fatigue, or abdominal pain occur, you should stop taking it immediately and inform healthcare personnel. Patients with poor kidney function, acute infections, dehydration, severe heart disease, or liver disease should not take this medication, and it should also be temporarily stopped before surgery or radiological examinations using contrast agents. In particular, it is safer not to use this medication in pregnant or nursing women, or in children under 18 years of age. During the treatment, hypoglycemia may occur, so if symptoms such as dizziness, cold sweat, or severe hunger arise, you should immediately consume sugar and consult a doctor. This medication may affect liver and kidney function, so regular blood tests and kidney function tests should be performed, and it is advisable to periodically check Vitamin B12 levels as well. Additionally, alcohol consumption can increase the risk of side effects from this medication, so you should avoid drinking alcohol while taking it. Lastly, while taking this medication, maintain regular meals and exercise, and if used in combination with other blood sugar-lowering medications, dose adjustments may be necessary to reduce the risk of hypoglycemia. Be sure to discuss other medications or health conditions with your doctor or pharmacist to use this safely.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is also recommended to store it at room temperature between 1 degree and 30 degrees Celsius. Proper storage will maintain the effectiveness and safety of the medication.
Light blue, double convex, oval-shaped extended release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.